Highlights Exact Sciences Corporation

Equities

EXAS

US30063P1057

Real-time Estimate Cboe BZX Other stock markets 17:23:19 09/05/2024 BST			5-day change	1st Jan Change
53.08 ^USD	-10.76%		-11.88%	-27.89%

05-08	Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours	MT
05-08	Transcript : Exact Sciences Corporation, Q1 2024 Earnings Call, May 08, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours	05-08	MT
Earnings Flash (EXAS) EXACT SCIENCES Reports Q1 Revenue $637.5M, vs. Street Est of $626.8M	05-08	MT
Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024	05-08	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sector Update: Health Care Stocks Advance Premarket Monday	04-15	MT
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes	04-11	MT
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	03-28	CI
Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $646.9M, vs. Street Est of $639.7M	02-21	MT
Exact Sciences Corporation Provides Earnings Guidance for the first quarter and Year 2024	02-21	CI
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Exact Sciences Sees 17% Growth in Q4 Revenue	01-08	MT
Exact Sciences Corporation Provides Revenue Guidance for the Year Ended December 31, 2023 and 2024	01-07	CI
Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients	12-01	CI
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy Over Colorectal Cancer Screening Test	11-17	MT
Exact Sciences Q3 EPS, Revenue Increase; Lifts 2023 Revenue Outlook	11-01	MT
Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M	11-01	MT
Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023	11-01	CI
Exact Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
Exact Sciences Corp. Announces Late-Breaking Data from the Pivotal Blue-C Trial	22/10/23	CI
Agilent Technologies to Sell Resolution Bioscience to Exact Sciences	12/09/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Exact Sciences Corporation

Equities

EXAS

US30063P1057

Highlights

Filters